On November 6, 3M fell 3.02% in Regular Trading, trading at $188.13, with turnover of $5.55 billion.
The most recent market-moving development was a fresh analyst target increase, with Goldman Sachs raising its price target on 3M to $225 from $200. This followed other recent target hikes, including JPMorgan to $210 from $191 and Bernstein to $197 from $171, indicating continued sell-side valuation reassessment.
Recent background news had already driven a sharp re-rating in the shares: 3M announced a broad PFAS personal injury settlement covering about 99% of current claims, with a nominal pre-tax commitment of $7.35 billion over nine years and a present value of about $5.8 billion. The company also approved a new $6 billion share repurchase authorization, in addition to an existing $1.5 billion program, while maintaining its dividend and stating the settlement does not change previously issued guidance. After that rally, the current move appears to reflect a pullback despite supportive analyst actions.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments